PDT Partners, LLC - VANDA PHARMACEUTICALS INC ownership

VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 160 filers reported holding VANDA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 12.90 and the average weighting 0.1%.

Quarter-by-quarter ownership
PDT Partners, LLC ownership history of VANDA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$263,158
-2.9%
39,9330.0%0.04%
-2.7%
Q1 2023$271,145
+36.9%
39,933
+99.0%
0.04%
+23.3%
Q3 2022$198,000
-55.5%
20,065
-50.8%
0.03%
-23.1%
Q2 2022$445,000
+72.5%
40,807
+79.1%
0.04%
+77.3%
Q1 2022$258,000
+32.3%
22,780
+82.9%
0.02%
+46.7%
Q4 2021$195,000
-84.4%
12,458
-78.5%
0.02%
-81.7%
Q2 2021$1,248,000
+45.8%
57,998
+1.8%
0.08%
+32.3%
Q1 2021$856,000
+41.7%
56,994
+24.0%
0.06%
+51.2%
Q4 2020$604,000
-23.4%
45,961
-43.7%
0.04%
-21.2%
Q3 2020$788,000
-29.4%
81,600
-16.3%
0.05%
-31.6%
Q2 2020$1,116,000
+257.7%
97,548
+223.7%
0.08%
+204.0%
Q1 2020$312,000
-80.5%
30,136
-69.4%
0.02%
-60.9%
Q2 2017$1,603,000
+5.2%
98,360
-9.6%
0.06%
-20.0%
Q1 2017$1,524,000
-12.2%
108,8600.0%0.08%
-29.8%
Q4 2016$1,736,000
-12.8%
108,860
-9.0%
0.11%
-2.6%
Q3 2016$1,991,000
+53.7%
119,660
+3.4%
0.12%
+13.6%
Q2 2016$1,295,000
+20.9%
115,760
-9.7%
0.10%
+53.7%
Q1 2016$1,071,000
-34.1%
128,160
-26.6%
0.07%
-70.0%
Q4 2015$1,625,000
-48.5%
174,560
-37.6%
0.22%
+214.1%
Q3 2015$3,155,000
+128.0%
279,715
+156.4%
0.07%
+97.2%
Q2 2015$1,384,000109,0900.04%
Other shareholders
VANDA PHARMACEUTICALS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Signpost Capital Advisors, LP 1,688,952$27,327,00010.37%
Palo Alto Investors LP 3,240,424$52,430,0003.90%
Parametrica Management Ltd 12,509$202,0001.53%
KINGDON CAPITAL MANAGEMENT, L.L.C. 1,740,400$28,160,0001.08%
PACIFIC ALTERNATIVE ASSET MANAGEMENT COMPANY, LLC 557,100$9,014,0001.07%
Westend Capital Management, LLC 64,086$841,0001.00%
WALL STREET ASSOCIATES 702,700$11,370,0000.98%
Baker Brothers Advisors 4,372,153$70,741,0000.87%
Iguana Healthcare Management, LLC 100,000$1,618,0000.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,085,301$17,560,0000.71%
View complete list of VANDA PHARMACEUTICALS INC shareholders